A Phase 2 interventional study of FMT Capsule + SIMBA Capsule in Obsessive-Compulsive Disorder, sponsored by Valerie Taylor. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-30.
Sponsored by Valerie Taylor · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Obsessive-Compulsive Disorder with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Obsessive-Compulsive Disorder · Canada.
Among the 52 studies in Obsessive-Compulsive Disorder with a site in Canada, this one is the 31st largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 2, reaches primary completion later than 0 of the 15 other live ones, and was the 42nd registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →12 of the 52 studies in Obsessive-Compulsive Disorder with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–85
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
University of Manitoba · Sites in Canada
Ages 6–24
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
Ciusss de L'Est de l'Île de Montréal · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 39 across the 47 interventional studies, 160 across the 5 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 52 have an industry lead sponsor. The 10 most frequent:
Valerie Taylor is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Valerie Taylor has 1 study filed under Obsessive-Compulsive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Obsessive-Compulsive Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01635569University of British ColumbiaClinical Outcomes in Pediatric Obsessive-Compulsive Disorder | 2027-06 |
| NCT07704632Sunnybrook Health Sciences CentreSafety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Obsessive-Compulsive Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obsessive-compulsive disorder (OCD) is a psychiatric condition marked by recurrent intrusive thoughts (obsessions) and ritualistic behaviors aimed at reducing distress (compulsions). While there exist a number of medications to treat this illness, half of those who need them either do not respond or can not tolerate current medications because of side effects. Therefore, there is an urgent need to develop new ways to treat this illness. One of the areas being explored as a potential option is based on what is now known as a strong link between the bacteria that live in our gut and the brain. Research has shown that a fecal transplant of the gut bacteria from healthy donors is able to improve health outcomes for people with depression and the investigators now want to expand this into OCD, given a known link between this condition and bacterial infection. To do this the investigators will use both the standard methods of bacterial identification via stool analysis, which looks at large bowel changes, and compare it to the Small Intestine Microbiome Aspiration (SIMBA) system, a small capsule that when swallowed allows a fluid sample to be collected from the participants' small intestine. This work will help the investigators assess the benefits of fecal transplant in OCD, and more importantly, identify how transplant changes the system, utilizing a novel technology to move the field forward.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
adults with OCD who are being treated with an approved first line treatment for OCD medication will be assigned to receive FMT capsules as an adjunct treatment.
Combination Product: FMT Capsule + SIMBA Capsule
Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
Adverse Events
Reported Adverse events
Time frame: 0-13 weeks
Toronto Side Effects Scale (TSES)
Changes in the Toronto Side Effects Scale (TSES). TSES a 32-item instrument used to evaluate the incidence, frequency, and severity of the central nervous system (CNS), gastrointestinal (GI), and sexual side effects.
Time frame: 0-13 weeks
Global function/overall improvement (Quick Inventory of Depressive Symptomatology-Self-Report (QIDS))
Quick Inventory of Depressive Symptomatology-Self-Report (QIDS). is a 16-item questionnaire that rates depression symptoms via self-assessment. Toral score is calculated but summing the scores of each of the 16 different questions. 0-5 Normal, 6-10 mild depression, 11-15 Moderate depression, 16-20 Severe depression and \>21 is considered very severe depression.
Time frame: 0-13 weeks
Global function/overall improvement (The General Anxiety Disorder-7 scale (GAD-7))
The General Anxiety Disorder-7 scale (GAD-7). The 7-item tool is used to screen and assess for generalized anxiety. Score 0-4: Minimal Anxiety, Score 5-9: Mild Anxiety, Score 10-14: Moderate Anxiety and Score greater than 15: Severe Anxiety
Time frame: 0-13 weeks
Global function/overall improvement (Positive and Negative Affect Schedule (PANAS))
Positive and Negative Affect Schedule (PANAS). The PANAS is a self-report questionnaire that consists of two 10-item scales and measures both positive and negative emotions for participants. The total score is calculated by finding the sum of the 10 positive items, and then the 10 negative items. Scores range from 10 - 50 for both sets of items. higher score indicates more positive or negative affect respectively.
Time frame: 0-13 weeks
Global function/overall improvement (Patient Health Questionnaire-9(PHQ9))
Patient Health Questionnaire-9(PHQ9). The PHQ9 is used for screening and measuring the severity of depressive symptoms. The total score is the sum the numbers of all the checked responses under each heading. Cut off scores are: 0 - 4 None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe and 20 - 27 Severe.
Time frame: 0-13 weeks
OCD symptoms (Y-BOCS)
Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Total scores range from 0 to 40. 0-7 indicates subclinical symptoms, 8-15 mild symptoms, 16-23 moderate symptoms, 24-31 severe symptoms and 32-40 extreme symptoms
Time frame: 0-13 weeks
OCD symptoms (TOCS)
Toronto Obsessive-Compulsive Scale (TOCS). TOCS is a 21 item self-reported questionnaire that assesses several major symptom dimensions in OCD. A total score is calculated by adding each score of the 21 items, and dimension scores are calculated by averaging the sum of item scores within each dimension.
Time frame: 0-13 weeks
Next generation fecal, Urine, Blood and saliva sequencing
analysis of Fecal, urine, blood and saliva samples
Time frame: 0-13 weeks
Plan to share: No — We will also share our results via the "Gut Microbiota for Health Experts exchange", an online community where experts in this field share news, innovation and information on topics pertaining to the gut microbiota (www.gutmicrobiotaforhealth.com). This organization has over 10 000 online members and a large social media presence. Manuscripts will be published in scientific journals
Started Jun 2023 (actual). Primary completion is estimated for Mar 2024, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →